Overview
Katherine Hoversten is a primary care provider, practicing in Internal Medicine in Rochester, Minnesota. Dr. Hoversten is rated as an Advanced provider by MediFind in the treatment of Felty Syndrome. Her top areas of expertise are Felty Syndrome, Chronic Myelomonocytic Leukemia (CMML), Philadelphia-Negative Chronic Myeloid Leukemia, and Splenomegaly.
Her clinical research consists of co-authoring 11 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Felty Syndrome.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- POS
- PPO
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Felty SyndromeDr. Hoversten isAdvanced. Learn about Felty Syndrome.
- Experienced
- BabesiosisDr. Hoversten isExperienced. Learn about Babesiosis.
- Chronic Myelomonocytic Leukemia (CMML)Dr. Hoversten isExperienced. Learn about Chronic Myelomonocytic Leukemia (CMML).
- LeukemiaDr. Hoversten isExperienced. Learn about Leukemia.
- Lyme DiseaseDr. Hoversten isExperienced. Learn about Lyme Disease.
- Lymphofollicular HyperplasiaDr. Hoversten isExperienced. Learn about Lymphofollicular Hyperplasia.
- Non-Small Cell Lung Cancer (NSCLC)Dr. Hoversten isExperienced. Learn about Non-Small Cell Lung Cancer (NSCLC).